

Additional file 2. Response per RECIST 1.1 Adjudicated by Independent Review Committee

	N=242
Confirmed BOR, n (%)	
Complete response	10 (4.1)
Partial response	30 (12.4)
Stable disease	65 (26.9)
Non-complete response/non-progressive disease	1 (0.4)
Progressive disease	93 (38.4)
Nonevaluable ^a	43 (17.8)
Confirmed ORR (95% CI), %	16.5 (12.1-21.8)
DCR, % ^b	43.8

BOR, best overall response; DCR, disease control rate; ORR, objective response rate; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1.

^a Missing and/or not-assessable information: 35 patients had no postbaseline tumor assessment, two patients had postbaseline assessments but response was not evaluable, five patients had stable disease of insufficient duration (<6 weeks after start date without further evaluable tumor assessment), and one patient was nonevaluable and had progressive disease >12 weeks after study assessment.

^b Proportion of patients with a best overall response of complete response, partial response, stable disease, and non-complete response/non-progressive disease.